ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 653

Newly Diagnosed Lupus Nephritis in Elderly Predicts Good Renal Outcome: A Distinct Disease Subset from Young-onset Lupus Nephritis

Kazuoto Hiramoto1, Hironari Hanaoka 1, Jun Kikuchi 1, Shuntaro Saito 1, Hiroshi Takei 2, Tatsuhiro Oshige 1, Noriyasu Seki 3, Hideto Tsujimoto 3, Yuko Kaneko 1 and Tsutomu Takeuchi 1, 1Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan, 2Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, 3Mitsubishi Tanabe Pharma Corporation Sohyaku. Innovative Research Division, Toda-shi, Saitama, Japan

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: Lupus nephritis, regulatory cells and Elderly, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 10, 2019

Title: SLE – Clinical Poster I: Epidemiology & Pathogenesis

Session Type: Poster Session (Sunday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Elderly-onset SLE is recognized to be benign disease entity with a favorable nature course. Although late-onset lupus nephritis (LN), long interval between onset of SLE and diagnosis of LN is associated with poor renal outcome, little information has been available in newly diagnosed LN in the elderly. The purpose of this study is to compare renal prognosis and clinical characteristics between elderly-onset and young-onset LN.

Methods: We reviewed SLE patients with LN from 2000 to 2018 in our hospital. LN was defined as biopsy-proven LN or persistent proteinuria (more than 0.5 g/gCr or ≥3+ for more than 3 months). Patients were classified into two groups based on disease onset: young-onset LN (< 50 years old) and elderly-onset LN (≥50 years old). Deterioration of renal function (more than 30% eGFR decline from baseline) and circulating regulatory T (Treg) cell counts were compared by fluorescence-activated cell sorting (FACS) analysis using anti-CD3, 4, 25, 127 antibodies between them.

Results: Fifty-three patients with young-onset LN and 9 with elderly-onset LN were evaluated. Baseline eGFR was significantly lower in patients with elderly-onset LN than young-onset LN (63.3±19.0 vs 93.4±23.5 ml/min, p< 0.01). There was no significant difference in baseline SLEDAI (16 vs 16, p=0.33), observational periods (8 vs 10, p=0.47), maximum dose of prednisolone (p=0.42), percentage of IVCY use (p=0.15) and MMF use (p=0.46) between the two groups. Cumulative deterioration rate of renal function tended to be lower in the elderly than young-onset LN (p=0.10, Figure 1). A higher tendency of peripheral Treg (CD3+/CD4+/CD25+/CD127dull) counts by FACS analysis was observed in the elderly than young-onset LN (p=0.60, Figure 2).

Conclusion: This study suggests that elderly-onset LN may have better renal prognosis than young-onset LN. Increasing number of peripheral Treg in the elderly-onset LN indicate that alteration of immune system by aging may influence the results. Adequate sample size and a longer period of observation may be required to verify the results.


Disclosure: K. Hiramoto, Mitsubishi Tanabe Pharma Corporation Sohyaku, 2; H. Hanaoka, Mitsubishi Tanabe Pharma Corporation Sohyaku, 2; J. Kikuchi, Mitsubishi Tanabe Pharma Corporation Sohyaku, 2; S. Saito, Mitsubishi Tanabe Pharma Corporation Sohyaku, 2; H. Takei, Mitsubishi Tanabe Pharma Corporation Sohyaku, 2; T. Oshige, Mitsubishi Tanabe Pharma Corporation Sohyaku, 2; N. Seki, Mitsubishi Tanabe Pharma Corporation, 3; H. Tsujimoto, Mitsubishi Tanabe Pharma Corporation, 3; Y. Kaneko, Mitsubishi Tanabe Pharma Corporation Sohyaku, 2; T. Takeuchi, Mitsubishi Tanabe Pharma Co., 2, 8, Mitsubishi Tanabe Pharma Corporation, 2, 5, 8.

To cite this abstract in AMA style:

Hiramoto K, Hanaoka H, Kikuchi J, Saito S, Takei H, Oshige T, Seki N, Tsujimoto H, Kaneko Y, Takeuchi T. Newly Diagnosed Lupus Nephritis in Elderly Predicts Good Renal Outcome: A Distinct Disease Subset from Young-onset Lupus Nephritis [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/newly-diagnosed-lupus-nephritis-in-elderly-predicts-good-renal-outcome-a-distinct-disease-subset-from-young-onset-lupus-nephritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/newly-diagnosed-lupus-nephritis-in-elderly-predicts-good-renal-outcome-a-distinct-disease-subset-from-young-onset-lupus-nephritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology